A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery.

Single-dose 10 mg rivaroxaban produced comparable systemic exposure before and after surgery, regardless of procedure type.

A noncontrolled, nonrandomized trial with risk-adapted dosing of rivaroxaban showed no thrombosis and low bleeding risk (0.9%).

Single doses of 5 mg apixaban at 1, 6, and 12 months resulted in no clinically significant changes in pharmacokinetic and pharmacodynamic parameters.

A randomized controlled trial in sleeve gastrectomy patients with twice daily prophylactic apixaban or low-molecular-weight heparin resulted in no venous thromboembolism and low rates of bleeding events (2%).